606147-37-9Relevant academic research and scientific papers
HIV PROTEASE INHIBITORS
-
Page/Page column 161-162, (2009/05/29)
Compounds of Formula I are disclosed: (I), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6, R6A, R7 and R8 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921
Singh, Janak,Kronenthal, David R.,Schwinden, Mark,Godfrey, Jollie D.,Fox, Rita,Vawter, Edward J.,Zhang, Bo,Kissick, Thomas P.,Patel, Bharat,Mneimne, Omar,Humora, Michael,Papaioannou, Chris G.,Szymanski, Walter,Wong, Michael K. Y.,Chen, Chien K.,Heikes, James E.,DiMarco, John D.,Qiu, Jun,Deshpande, Rajendra P.,Gougoutas, Jack Z.,Mueller, Richard H.
, p. 3155 - 3158 (2007/10/03)
(Matrix presented) An efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921 was accomplished. Two short enantioselective syntheses of the common key intermediate (S)-α-aminoazepinone 6b were developed. Olefin 3 was converted to 6b via a
